• Explore /
  • Poster
  • / REGOMUNE: Phase II study of regorafenib plus avelumab in solid tumors—Results of the gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) cohort.

REGOMUNE: Phase II study of regorafenib plus avelumab in solid tumors—Results of the gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) cohort.

Abstract Poster

Authors

null

Sophie Cousin

Early Phase Clinical Trials Unit and Thoracic Unit, Institut Bergonié, Bordeaux, France

Sophie Cousin , Carine A. Bellera , Jean Philippe Guégan , Fabienne Portales , Antoine Hollebecque , Jean Philippe Metges , Philippe Alexandre Cassier , Carlos A. Gomez-Roca , Fanny Bouteiller , Michèle Kind , Jean Palussière , Simon Pernot , Isabelle Soubeyran , Alban Bessede , Antoine Italiano

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Neuroendocrine/Carcinoid

Clinical Trial Registration Number

NCT03475953

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4125)

DOI

10.1200/JCO.2022.40.16_suppl.4125

Abstract #

4125

Poster Bd #

111

Abstract Disclosures

Similar Posters

First Author: Peter C. Thuss-Patience

First Author: Sophie Cousin

First Author: Greg Andrew Durm

Poster

2020 ASCO Virtual Scientific Program

TROPiCS–03: A phase II open-label study of sacituzumab govitecan (SG) in patients with metastatic solid tumors.

TROPiCS–03: A phase II open-label study of sacituzumab govitecan (SG) in patients with metastatic solid tumors.

First Author: Ashish Saxena